BR0108694A - Derivados de ácido malÈnico, processo para preparação dos mesmos, uso dos mesmos como inibidor de atividade do fator xa e composições farmacêuticas que contêm os mesmos - Google Patents
Derivados de ácido malÈnico, processo para preparação dos mesmos, uso dos mesmos como inibidor de atividade do fator xa e composições farmacêuticas que contêm os mesmosInfo
- Publication number
- BR0108694A BR0108694A BR0108694-4A BR0108694A BR0108694A BR 0108694 A BR0108694 A BR 0108694A BR 0108694 A BR0108694 A BR 0108694A BR 0108694 A BR0108694 A BR 0108694A
- Authority
- BR
- Brazil
- Prior art keywords
- formula
- factor
- activity
- same
- compounds
- Prior art date
Links
- 108010074860 Factor Xa Proteins 0.000 title abstract 5
- 230000000694 effects Effects 0.000 title abstract 4
- 239000003112 inhibitor Substances 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 239000002253 acid Substances 0.000 title abstract 2
- 238000004519 manufacturing process Methods 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 7
- 230000023555 blood coagulation Effects 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 3
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 239000000126 substance Substances 0.000 abstract 2
- 101000882917 Penaeus paulensis Hemolymph clottable protein Proteins 0.000 abstract 1
- 208000001435 Thromboembolism Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 150000002690 malonic acid derivatives Chemical class 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/56—Amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C257/00—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines
- C07C257/10—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines
- C07C257/18—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines having carbon atoms of amidino groups bound to carbon atoms of six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
- C07C279/04—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
- C07C279/14—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Crystallography & Structural Chemistry (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP00104041A EP1127884A1 (en) | 2000-02-26 | 2000-02-26 | Novel malonic acid derivatives, processes for their preparation, their use as inhibitor of factor XA activity and pharmaceutical compositions containing them |
| PCT/EP2001/001928 WO2001062735A1 (en) | 2000-02-26 | 2001-02-21 | Novel malonic acid derivatives, processes for their preparation, their use as inhibitor of factor xa activity and pharmaceutical compositions containing them |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0108694A true BR0108694A (pt) | 2002-12-10 |
Family
ID=8167968
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0108694-4A BR0108694A (pt) | 2000-02-26 | 2001-02-21 | Derivados de ácido malÈnico, processo para preparação dos mesmos, uso dos mesmos como inibidor de atividade do fator xa e composições farmacêuticas que contêm os mesmos |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US6794365B2 (enExample) |
| EP (2) | EP1127884A1 (enExample) |
| JP (1) | JP2003524001A (enExample) |
| KR (1) | KR20020079892A (enExample) |
| CN (1) | CN1406226A (enExample) |
| AR (1) | AR027533A1 (enExample) |
| AT (1) | ATE314350T1 (enExample) |
| AU (1) | AU2001235486A1 (enExample) |
| BR (1) | BR0108694A (enExample) |
| CA (1) | CA2400871C (enExample) |
| CZ (1) | CZ20022862A3 (enExample) |
| DE (1) | DE60116272T2 (enExample) |
| ES (1) | ES2254370T3 (enExample) |
| HK (1) | HK1052696A1 (enExample) |
| HU (1) | HUP0300080A3 (enExample) |
| IL (1) | IL151459A0 (enExample) |
| MX (1) | MXPA02007398A (enExample) |
| NO (1) | NO20024040L (enExample) |
| NZ (1) | NZ520982A (enExample) |
| PL (1) | PL357183A1 (enExample) |
| RU (1) | RU2002125671A (enExample) |
| WO (1) | WO2001062735A1 (enExample) |
| ZA (1) | ZA200206581B (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030224023A1 (en) * | 2002-05-29 | 2003-12-04 | Unilever Home & Personal Care Usa, Division Of Conopco, Inc. | Cosmetic compositions with hydroxy amine salts of malonic acid |
| US20040202689A1 (en) * | 2003-03-17 | 2004-10-14 | Unilever Home & Personal Care Usa, Division Of Conopco, Inc. | Terpenoid fragrance components stabilized with malonic acid salts |
| US20040185015A1 (en) * | 2003-03-17 | 2004-09-23 | Unilever Home & Personal Care Usa, Division Of Conopco, Inc. | Sunscreen cosmetic compositions storage stabilized with malonate salts |
| US20040185074A1 (en) * | 2003-03-17 | 2004-09-23 | Unilever Home & Personal Care Usa, Division Of Conopco, Inc. | Odor control in amine salt containing cosmetic compositions |
| US20040185073A1 (en) * | 2003-03-17 | 2004-09-23 | Unilever Home & Personal Care Usa, Division Of Conopco, Inc. | Cosmetic compositions containing salts of malonic acid |
| US20080194643A1 (en) * | 2005-03-24 | 2008-08-14 | Pfzer Inc | Factor Xa Inhibitor Crystalline Forms |
| US9249265B1 (en) | 2014-09-08 | 2016-02-02 | Sirrus, Inc. | Emulsion polymers including one or more 1,1-disubstituted alkene compounds, emulsion methods, and polymer compositions |
| EP2630191A4 (en) | 2010-10-20 | 2015-05-20 | Sirrus Inc | SYNTHESIS SUBSTANTIALLY CLEANING METHYLENE MALONATES |
| US9279022B1 (en) | 2014-09-08 | 2016-03-08 | Sirrus, Inc. | Solution polymers including one or more 1,1-disubstituted alkene compounds, solution polymerization methods, and polymer compositions |
| US9828324B2 (en) | 2010-10-20 | 2017-11-28 | Sirrus, Inc. | Methylene beta-diketone monomers, methods for making methylene beta-diketone monomers, polymerizable compositions and products formed therefrom |
| US10414839B2 (en) | 2010-10-20 | 2019-09-17 | Sirrus, Inc. | Polymers including a methylene beta-ketoester and products formed therefrom |
| EP3339301A3 (en) | 2011-10-19 | 2018-08-08 | Sirrus, Inc. | Methods for making methylene beta-diketone monomers |
| CA2869108A1 (en) | 2012-03-30 | 2013-10-03 | Bioformix Inc. | Methods for activating polymerizable compositions, polymerizable systems, and products formed thereby |
| EP3626784A1 (en) | 2012-03-30 | 2020-03-25 | Sirrus, Inc. | Ink and coating formulations and polymerizable systems for producing the same |
| US10913875B2 (en) | 2012-03-30 | 2021-02-09 | Sirrus, Inc. | Composite and laminate articles and polymerizable systems for producing the same |
| US10047192B2 (en) | 2012-06-01 | 2018-08-14 | Sirrus, Inc. | Optical material and articles formed therefrom |
| CN105008438B (zh) | 2012-11-16 | 2019-10-22 | 拜奥福米克斯公司 | 塑料粘结体系及方法 |
| CN105164797B (zh) | 2012-11-30 | 2019-04-19 | 瑟拉斯公司 | 用于电子应用的复合组合物 |
| WO2014110388A1 (en) | 2013-01-11 | 2014-07-17 | Bioformix Inc. | Method to obtain methylene malonate via bis(hydroxymethyl) malonate pathway |
| US9315597B2 (en) | 2014-09-08 | 2016-04-19 | Sirrus, Inc. | Compositions containing 1,1-disubstituted alkene compounds for preparing polymers having enhanced glass transition temperatures |
| US9416091B1 (en) | 2015-02-04 | 2016-08-16 | Sirrus, Inc. | Catalytic transesterification of ester compounds with groups reactive under transesterification conditions |
| US10501400B2 (en) | 2015-02-04 | 2019-12-10 | Sirrus, Inc. | Heterogeneous catalytic transesterification of ester compounds with groups reactive under transesterification conditions |
| US9334430B1 (en) | 2015-05-29 | 2016-05-10 | Sirrus, Inc. | Encapsulated polymerization initiators, polymerization systems and methods using the same |
| US9217098B1 (en) | 2015-06-01 | 2015-12-22 | Sirrus, Inc. | Electroinitiated polymerization of compositions having a 1,1-disubstituted alkene compound |
| US9518001B1 (en) | 2016-05-13 | 2016-12-13 | Sirrus, Inc. | High purity 1,1-dicarbonyl substituted-1-alkenes and methods for their preparation |
| US9617377B1 (en) | 2016-06-03 | 2017-04-11 | Sirrus, Inc. | Polyester macromers containing 1,1-dicarbonyl-substituted 1 alkenes |
| US9567475B1 (en) | 2016-06-03 | 2017-02-14 | Sirrus, Inc. | Coatings containing polyester macromers containing 1,1-dicarbonyl-substituted 1 alkenes |
| US10196481B2 (en) | 2016-06-03 | 2019-02-05 | Sirrus, Inc. | Polymer and other compounds functionalized with terminal 1,1-disubstituted alkene monomer(s) and methods thereof |
| US10428177B2 (en) | 2016-06-03 | 2019-10-01 | Sirrus, Inc. | Water absorbing or water soluble polymers, intermediate compounds, and methods thereof |
| CN106501472A (zh) * | 2016-11-29 | 2017-03-15 | 昆明理工大学 | 一种基于抗凝血生化指数评价三七活血作用的方法 |
| CN111018734B (zh) * | 2019-12-13 | 2020-12-22 | 福建海西新药创制有限公司 | 一种盐酸西那卡塞中间体的合成方法 |
| IL316963A (en) * | 2022-05-20 | 2025-01-01 | Radius Health Inc | Process for preparing avalopretide |
| CN115299636B (zh) * | 2022-08-17 | 2025-02-14 | 中国烟草总公司郑州烟草研究院 | 一种卷烟滤嘴用功能吸附丸芯及其制备方法和烟支 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU8866882A (en) * | 1981-09-25 | 1983-03-31 | Wellcome Foundation Limited, The | 2-(n-hydroxycarbamoyl)phenylpropanoyl amino acids |
| WO1992008709A1 (de) * | 1990-11-15 | 1992-05-29 | Pentapharm Ag | Meta-substituierte phenylalanin-derivate |
| JPH07509731A (ja) * | 1993-02-10 | 1995-10-26 | ペンタファルム アクチェンゲゼルシャフト | トロンビン阻害剤としての置換されたフェニルアラニン誘導体のピペラジド |
| NZ284977A (en) * | 1994-04-26 | 1998-09-24 | Selectide Corp | Factor xa enzyme inhibitor |
| WO1996005189A1 (de) * | 1994-08-09 | 1996-02-22 | Pentapharm Ag | Neue inhibitoren vom benzamidintyp |
| UA48993C2 (uk) * | 1995-12-20 | 2002-09-16 | Авентіс Фармасьютікалз, Інк | СПОСІБ ОТРИМАННЯ N-АЦЕТИЛ-(L)-4-ЦІАНОФЕНІЛАЛАНІНУ Аc-(L)-Phe(4-CN)-OH І N-АЦЕТИЛ-(L)-П-АМІДИНФЕНІЛАЛАНІН-ЦИКЛОГЕКСИЛГЛІЦИН-<font face="Symbol">b</font>-(3-N-МЕТИЛПІРИДИН)-АЛАНІНУ Аc-(L)-pАph-Сhg-PalMe(3)-NH<sub>2</sub> |
| ES2218827T3 (es) * | 1997-05-02 | 2004-11-16 | Akzo Nobel N.V. | Inhibidores de la serina proteasa. |
| ATE344246T1 (de) * | 1997-11-26 | 2006-11-15 | Ortho Mcneil Pharm Inc | Heteroaryl aminoguanidin- und alkoxyguanidinderivate und ihre verwendung als proteasehemmer |
| PT1042287E (pt) | 1997-12-24 | 2005-08-31 | Aventis Pharma Gmbh | Derivados de indole como inibidores do factor xa |
| JP3283485B2 (ja) * | 1998-04-10 | 2002-05-20 | 日本たばこ産業株式会社 | アミジン化合物 |
| NZ512669A (en) | 1999-01-02 | 2003-11-28 | Aventis Pharma Gmbh | Arylalkanoyl derivatives, processes for their preparation, their use and pharmaceutical compositions containing them |
| CA2358578A1 (en) * | 1999-01-02 | 2000-07-13 | Aventis Pharma Deutschland Gmbh | Novel malonic acid derivatives, processes for their preparation, their use and pharmaceutical compositions containing them (inhibition of factor xa activity) |
| EP1016663A1 (en) * | 1999-01-02 | 2000-07-05 | Aventis Pharma Deutschland GmbH | Novel malonic acid derivatives, processes for their preparation, their use and pharmaceutical compositions containing them (inhibition of factor Xa activity) |
-
2000
- 2000-02-26 EP EP00104041A patent/EP1127884A1/en not_active Withdrawn
-
2001
- 2001-02-21 ES ES01907546T patent/ES2254370T3/es not_active Expired - Lifetime
- 2001-02-21 DE DE60116272T patent/DE60116272T2/de not_active Expired - Lifetime
- 2001-02-21 HU HU0300080A patent/HUP0300080A3/hu unknown
- 2001-02-21 RU RU2002125671/04A patent/RU2002125671A/ru not_active Application Discontinuation
- 2001-02-21 NZ NZ520982A patent/NZ520982A/en unknown
- 2001-02-21 HK HK03104942.8A patent/HK1052696A1/zh unknown
- 2001-02-21 WO PCT/EP2001/001928 patent/WO2001062735A1/en not_active Ceased
- 2001-02-21 KR KR1020027011004A patent/KR20020079892A/ko not_active Withdrawn
- 2001-02-21 EP EP01907546A patent/EP1265867B1/en not_active Expired - Lifetime
- 2001-02-21 JP JP2001562517A patent/JP2003524001A/ja active Pending
- 2001-02-21 PL PL01357183A patent/PL357183A1/xx not_active Application Discontinuation
- 2001-02-21 CN CN01805589A patent/CN1406226A/zh active Pending
- 2001-02-21 AT AT01907546T patent/ATE314350T1/de not_active IP Right Cessation
- 2001-02-21 CA CA2400871A patent/CA2400871C/en not_active Expired - Fee Related
- 2001-02-21 IL IL15145901A patent/IL151459A0/xx unknown
- 2001-02-21 MX MXPA02007398A patent/MXPA02007398A/es active IP Right Grant
- 2001-02-21 CZ CZ20022862A patent/CZ20022862A3/cs unknown
- 2001-02-21 AU AU2001235486A patent/AU2001235486A1/en not_active Abandoned
- 2001-02-21 BR BR0108694-4A patent/BR0108694A/pt not_active Application Discontinuation
- 2001-02-22 AR ARP010100806A patent/AR027533A1/es not_active Application Discontinuation
- 2001-02-23 US US09/790,641 patent/US6794365B2/en not_active Expired - Lifetime
-
2002
- 2002-08-16 ZA ZA200206581A patent/ZA200206581B/en unknown
- 2002-08-23 NO NO20024040A patent/NO20024040L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| NO20024040D0 (no) | 2002-08-23 |
| NO20024040L (no) | 2002-09-24 |
| IL151459A0 (en) | 2003-04-10 |
| AR027533A1 (es) | 2003-04-02 |
| MXPA02007398A (es) | 2002-12-09 |
| CZ20022862A3 (cs) | 2002-11-13 |
| EP1265867B1 (en) | 2005-12-28 |
| AU2001235486A1 (en) | 2001-09-03 |
| KR20020079892A (ko) | 2002-10-19 |
| ES2254370T3 (es) | 2006-06-16 |
| HUP0300080A3 (en) | 2004-07-28 |
| ZA200206581B (en) | 2003-07-28 |
| ATE314350T1 (de) | 2006-01-15 |
| EP1265867A1 (en) | 2002-12-18 |
| PL357183A1 (en) | 2004-07-26 |
| RU2002125671A (ru) | 2004-01-10 |
| US20020022596A1 (en) | 2002-02-21 |
| US6794365B2 (en) | 2004-09-21 |
| CN1406226A (zh) | 2003-03-26 |
| HK1052696A1 (zh) | 2003-09-26 |
| CA2400871A1 (en) | 2001-08-30 |
| JP2003524001A (ja) | 2003-08-12 |
| DE60116272D1 (de) | 2006-02-02 |
| DE60116272T2 (de) | 2006-08-17 |
| HUP0300080A2 (hu) | 2003-06-28 |
| WO2001062735A1 (en) | 2001-08-30 |
| NZ520982A (en) | 2004-05-28 |
| CA2400871C (en) | 2011-04-26 |
| EP1127884A1 (en) | 2001-08-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0108694A (pt) | Derivados de ácido malÈnico, processo para preparação dos mesmos, uso dos mesmos como inibidor de atividade do fator xa e composições farmacêuticas que contêm os mesmos | |
| BR9916732A (pt) | Derivados de ácido malÈnico, processo para a sua preparação, seu uso e composições farmacêuticas contendo-os (inibição da atividade do fator xa) | |
| BR9814340A (pt) | Derivados de indol como inibidores de fator xa | |
| BR9806870A (pt) | Composto, processo para a profilaxia ou tratamento de uma condição clìnica em um mamìfero, formulação farmacêutica, e, uso de um composto e processo para preparar o mesmo. | |
| BRPI0312464B8 (pt) | compostos inibidores de tirosina quinases, composições farmacêuticas compreendendo os mesmos, processos para fabricação e usos dos mesmos | |
| BR9910849A (pt) | Composto, processo para a profilaxia ou tratamento de uma condição clìnica em um mamìfero, tal como um humano, formulação farmacêutica, uso de um composto, processo para preparação do composto, e, derivado protegido. | |
| BR9907270A (pt) | Composto, composição farmacêutica, uso de um composto, e, processos para tratamento ou profilaxia de doenças inflamatórias, por exemplo, asma ou copd, e para a preparação de um composto | |
| BRPI0410037A (pt) | inibidores da fosfatidilinositol 3-cinase | |
| MXPA04012965A (es) | Inhibidores virales. | |
| BR0209821A (pt) | Compostos, processo para a manufatura desses compostos, composições farmacêuticas que compreendem os mesmos, processo para o tratamento e/ou profilaxia de enfermidades e utilização dos compostos | |
| BR9911482A (pt) | Composto, composição farmacêutica, uso do composto, e, processos para o tratamento ou profilaxia de doenças inflamatórias, e para a preparação de um composto | |
| BR0114321A (pt) | Composto, composição farmacêutica, uso de um composto, método de tratamento ou profilaxia de doenças inflamatórias, e, processo para preparar um composto | |
| BRPI0409227B8 (pt) | "composto, composição farmacêutica, uso de um composto e processo para a preparação de um composto de fórmula (i)" | |
| BR0314071A (pt) | Derivados de pró-droga de 1,3-diamino-2-hidroxipropano | |
| BR9808953A (pt) | Composto, processo para tratar um distúrbio mediado pela ciclooxigenase-2 em um paciente, e, composição farmacêutica | |
| BRPI0411255A (pt) | composto, composição farmacêutica, uso de um composto, métodos de tratar um distúrbio de um paciente, e, processo para a preparação de um composto | |
| BR0312633A (pt) | Composto, uso do composto, composição farmacêutica, processo para a preparação de um composto | |
| BR9810592A (pt) | Composto, processos para preparar um composto, para tratar ou prevenir doenças do sistema endócrino e para a fabricação de um medicamento, composição farmacêutica, e, uso de um composto | |
| BR0212346A (pt) | Composto ou um sal farmaceuticamente aceitável, solvato, solvato deste sal ou uma pró-droga do mesmo, processo para a preparação do mesmo, uso deste, método para produzir um efeito inibidor de ibat em um animal de sangue quente, como um humano, em necessidade deste tratamento, e, composição farmacêutica | |
| BR0212344A (pt) | Composto, processo para preparar um composto, uso de um composto, método para produzir um efeito inibidor de ácido de bile ileal em um animal de sangue quente e composição farmacêutica | |
| DE60225556D1 (de) | Dpp-iv-inhibierende purin-derivative zur behandlung von diabetes | |
| BR0210838A (pt) | Composto, formulação farmacêutica, uso de um composto, métodos de prevenção e/ou tratamento de condições associadas com glicogênio sintase quinase-3, e de doenças, e medicação contraceptiva, e, processos para a preparação de um composto | |
| BRPI0518846A2 (pt) | composto, composiÇço farmacÊutica, mÉtodos de tratar, ou reduzir o risco de doenÇas ou condiÇÕes em que inibiÇço da enzima mpo É benÉfica e de tratar, ou reduzir o risco de distérbios neuroinflamatàrios, uso de um composto, e, processo para a preparaÇço de um composto | |
| PT1008588E (pt) | Derivados da 11,15-o-diaklquil-prostaglandina e processo de producao dos mesmos e farmaco que os contem como ingrediente activo | |
| BR0309498A (pt) | Compostos, composições farmacêuticas, método para o tratamento ou profilaxia de doenças que são relacionadas com o ras, e, uso de compostos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25D | Requested change of name of applicant approved |
Owner name: SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) Free format text: ALTERADO DE: AVENTIS PHARMA DEUTSCHLAND GMBH |
|
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |